Compare Vanguard Mega Cap Growth ETF (MGK) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Vanguard Mega Cap Growth ETF trades at $91.36 (market cap $33.70B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Vanguard Mega Cap Growth ETF is far larger — about 34.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Mega Cap Growth ETF for 45 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MGK | MRVI | |
|---|---|---|
Market Cap | $33.70B | $972.90M |
Volume | 775,002 | 4,325,710 |
Sector | Broad Market / Factor | Health |
52-Week High | $95.11 | $9.00 |
52-Week Low | $70.70 | $2.83 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $94.19, up 0.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking large-cap U.S. growth stocks like Nvidia and Apple, lacks disclosed fundamental ratios but benefits from a low 0.05% expense ratio and recent positive media coverage highlighting its long-term growth potential and tech concentration.
The outlook for MGK is favorable for growth-oriented investors, driven by its focus on mega-cap tech leaders, though concentration risk and market volatility pose challenges. Analyst sentiment is broadly positive, with the ETF positioned to capitalize on sustained growth trends, but investors should weigh its reliance on top holdings against diversification needs.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
